EtiraRX has filed a notice of an exempt offering of securities to raise $10,595,149.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, EtiraRX is raising $10,595,149.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Russell Hayward played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About EtiraRX
BioPharma research company developing solutions for Therapy Resistant Metastatic Breast Cancer. We are a company committed to making a difference in the lives of patients with untreatable therapy-resistant cancers. Our innovative therapies overcome tumor heterogeneity, which is the primary obstacle to effective cancer therapy. We believe that our pipelines hold the promise of tomorrow’s treatments.
We venture where others won’t.
To learn more about EtiraRX, visit http://www.etirarx.com/
Contact:
Russell Hayward, Chief Executive Officer
469-600-6603
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.